Skip to content
DataLookout
Menu

NCT05291676

Systems Investigation of Vaccine Responses in Aging and Frailty

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 7 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Apr 2027 to May 2029 Show 4 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description revised
    • Site contact updated
  2. Notable Eligibility criteria revised
    • Study sites: 2 to 1
    v8
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2023 to Nov 6, 2023
    • Site details revised at 2 of 2 sites
    v7
  4. Notable Primary endpoint revised
    • Secondary endpoints: 4 to 5
    v5
  5. Minor Primary and study completion dates: Jul 2027 to Apr 2027v3
  6. Notable Start date: Aug 2022 to Sep 2023
    • Primary and study completion dates: Jan 2027 to Jul 2027
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in production of IL-6 in monocytes to assess innate immune inflammatory response
Timeframe: Baseline and at Day 2, 7, and 28 post-vaccine

Secondary (5)

Change in Hemagglutination inhibition titer (HAI) in response to vaccination
Change in transcriptomic analyses of gene expression
Change in proteomic analyses
Number of participants with changes in innate immune function from PBMCs and PRP as assessed using flow cytometry
Number of participants with changes in B and T cell function from PBMCs as assessed using flow cytometry

Arms and interventions

21-30 standard dose FluadActive comparator

Participants age 21-30 years will receive the standard dose Fluad

21-30 high dose FluzoneActive comparator

Participants age 21-30 years will receive the high dose Fluzone

≥65 years standard dose FluadExperimental

Participants age ≥65 years will receive standard dose Fluad

≥65 years high dose FluzoneExperimental

Participants age ≥65 years will receive high dose Fluzone

Biologicals: Fluzone, Fluad

Sites

1 site in 1 country

  • Yale School of MedicineNew Haven, Connecticut, United States